| Autor: |
Swaans MJ; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands., Wintgens LI; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands., Alipour A; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands., Rensing BJ; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands., Boersma LV; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. |
| Abstrakt: |
Atrial fibrillation (AF) is the most common arrhythmia treated in the clinical practice. One of the major complications of AF is a thromboembolic cerebral ischemic event. Up to 20% of all strokes are caused by AF. Thromboembolic cerebral ischemic event in patients with AF occurs due to atrial thrombi, mainly from the left atrial appendage (LAA). Prevention of clot formation with antiplatelet agents and especially oral anticoagulants (vitamin K antagonists or newer oral anticoagulants) has been shown to be effective in reducing the stroke risk in patients with AF but has several drawbacks with (major) bleedings as the most important disadvantage. Therefore, physical elimination of the LAA, which excludes the site of clot formation by surgical or percutaneous techniques, might be a good alternative. In this review, we discuss the safety, efficacy, and clinical utility of the Watchman™ LAA closure device. |
